ENTPD1 and neoplasm: Yujia Zheng also reported that tocilizumab prevented CD39 expression on NK cells induced by IL6 derived by esophageal squamous cell carcinoma cells, which suggested that tocilizumab may inhibit tumor growth via affecting NK cells [52].